These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21370008)

  • 1. Automated analysis of FISH-stained HER2/neu samples with Metafer.
    Schunck C; Mohammad E
    Methods Mol Biol; 2011; 724():91-103. PubMed ID: 21370008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
    Yoon N; Do IG; Cho EY
    APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
    Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
    Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.
    Moatamed NA; Nanjangud G; Pucci R; Lowe A; Shintaku IP; Shapourifar-Tehrani S; Rao N; Lu DY; Apple SK
    Am J Clin Pathol; 2011 Nov; 136(5):754-61. PubMed ID: 22031314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients.
    Ozer O; Sahin FI; Aydemir F; Ozen O; Yilmaz Z; Altinörs N
    Turk Neurosurg; 2009 Apr; 19(2):135-8. PubMed ID: 19431122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
    Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.
    Bánkfalvi A; Boecker W; Reiner A
    Int J Oncol; 2004 Oct; 25(4):929-35. PubMed ID: 15375542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.
    Ratcliffe N; Wells W; Wheeler K; Memoli V
    Mod Pathol; 1997 Dec; 10(12):1247-52. PubMed ID: 9436971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
    Narath R; Lörch T; Rudas M; Ambros PF
    Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
    Shafizadeh N; Grenert JP; Sahai V; Kakar S
    Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.
    Park K; Kim J; Lim S; Han S; Lee JY
    Mod Pathol; 2003 Sep; 16(9):937-43. PubMed ID: 13679458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
    Pauletti G; Godolphin W; Press MF; Slamon DJ
    Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.